Neoadjuvant immunotherapy leads to pathological responses in MMR-proficient and MMR-deficient early-stage colon cancers

Myriam Chalabi(The Netherlands Cancer Institute), Lorenzo F. Fanchi(The Netherlands Cancer Institute), Krijn K. Dijkstra(The Netherlands Cancer Institute), José G. van den Berg(The Netherlands Cancer Institute), Arend G. J. Aalbers(The Netherlands Cancer Institute), Karolina Sikorska(Dutch Cancer Society), Marta López‐Yurda(Dutch Cancer Society), Cecile Grootscholten(The Netherlands Cancer Institute), Geerard L. Beets(The Netherlands Cancer Institute), Pétur Snæbjörnsson(The Netherlands Cancer Institute), Monique Maas(The Netherlands Cancer Institute), Marjolijn Mertz(The Netherlands Cancer Institute), Vivien Veninga(The Netherlands Cancer Institute), Gergana Bounova(Oncode Institute), Annegien Broeks(The Netherlands Cancer Institute), Regina G. H. Beets‐Tan(The Netherlands Cancer Institute), Thomas R. de Wijkerslooth(The Netherlands Cancer Institute), Anja U. van Lent(OLVG), Hendrik A. Marsman(OLVG), Elvira Nuijten(Dutch Cancer Society), Niels F. M. Kok(The Netherlands Cancer Institute), Maria Kuiper(The Netherlands Cancer Institute), Wieke H.M. Verbeek(The Netherlands Cancer Institute), Marleen Kok(The Netherlands Cancer Institute), Monique E. van Leerdam(The Netherlands Cancer Institute), Ton N. Schumacher(The Netherlands Cancer Institute), Emile E. Voest(Oncode Institute), John B.A.G. Haanen(The Netherlands Cancer Institute)
Nature Medicine
April 1, 2020
Cited by 1,377Open Access
Full Text

Abstract


Related Papers

No related papers found

Powered by citation graph analysis